364 filings
Page 14 of 19
CORRESP
lfh1gev77u
15 Mar 11
Correspondence with SEC
12:00am
UPLOAD
e87d lm79a4
14 Mar 11
Letter from SEC
12:00am
6-K
mcr tdwbi3zkf029
8 Mar 11
Current report (foreign)
12:00am
D/A
2h8f6
7 Mar 11
$2.73M in equity / options / securities to be acquired, sold $2.73M, 13 investors
12:00am
D/A
ri7h9d kywv
7 Mar 11
$2.5M in equity / options / securities to be acquired, sold $2.5M, 17 investors
12:00am
F-3
lfqorvt
7 Mar 11
Shelf registration (foreign)
12:00am
D
o6fm6 it2f
3 Mar 11
$2.73M in equity / options / securities to be acquired, sold $2.73M, 13 investors
12:00am
D
ag1pbw9wn dj
3 Mar 11
$2.5M in equity / options / securities to be acquired, sold $2.5M, 17 investors
12:00am
6-K
9jy0tb7op8zd vd
22 Feb 11
Rosetta Genomics Announces IPO of Majority-owned Subsidiary Rosetta Green In Israel
12:00am
6-K
424ces d9208h6f3ca
18 Feb 11
Current report (foreign)
12:00am
424B5
8y8hz0zr4cosqmynac
17 Feb 11
Prospectus supplement for primary offering
12:00am
6-K
2yaebtfoa31k17
8 Feb 11
Rosetta Genomics Receives NASDAQ Extensions
12:00am
6-K
x1oi2wuv6u
1 Feb 11
Rosetta Genomics Advances Development of its Body Fluids-Based
12:00am
6-K/A
pdwpi8f
24 Jan 11
Current report (foreign) (amended)
12:00am
6-K
1641jvjoouy c194brtg
3 Jan 11
Rosetta Genomics Receives New York State Clinical Laboratory
12:00am
424B3
i7m4rl mkxefoskgwv3
23 Dec 10
Prospectus supplement
12:00am
EFFECT
frbk 1lpj
22 Dec 10
Notice of effectiveness
12:00am
6-K
8bw0q0 u286ji6
21 Dec 10
Current report (foreign)
12:00am
F-3
14jf7v7xf
16 Dec 10
Shelf registration (foreign)
12:00am
6-K
37rag ahqb5qtyeyv9t9
13 Dec 10
Rosetta Genomics Announces the Availability of miRview® mets², a Second Generation Version of miRview® mets
12:00am